MannKind Corporation share price logo

MannKind Corporation

NASDAQ: MNKD

Small Cap

$3.94

+0.02

(+0.51%)

as on

MannKind Corporation Stock Performance

as on June 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $3.83
    $4.01
    downward going graph

    2.79%

    Downside

    1.78%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.23
    $6.51
    downward going graph

    43.40%

    Downside

    65.23%

    Upside

    downward going graph

MannKind Corporation share price movements today

Previous Close
$3.92
Open
$4.01
Volume
3.7M
Day's Low - High
$3.83 - $4.01
52 Week Low - High
$2.23 - $6.51

MannKind Corporation Historical Returns

1 Month Return
+ 33.11 %
3 Month Return
+ 56.35 %
1 Year Return
+ 3.41 %
3 Year Return
-3.67 %
5 Year Return
-7.51 %

MannKind Corporation Stock Fundamentals & Key Indicators

Check MannKind Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.2B

EPS (TTM)

0.085

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.35%

PE Ratio (TTM)

0

PEG Ratio

4.3866

EBITDA

35.3M

Revenue (TTM)

360.8M

Profit Margin

-6.63%

Return On Equity TTM

0.00%

MannKind Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MannKind Corporation with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
MannKind Corporation image
MannKind Corporation
BUY$1.2B-7.51%NA-6.63%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for MannKind Corporation Stock including INR - Dollar returns

The MannKind Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

MannKind Corporation investment value today

Current value as on today

₹1,12,645

Returns

₹12,645

(+12.64%)

Returns from MannKind Corporation Stock

₹3,412 (+3.41%)

Dollar Impact

₹9,233 (+9.23%)

Analyst Recommendation on MannKind Corporation Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for MannKind Corporation. Average target price of $7.59

MannKind Corporation Share Price Target

Get share price movements and forecasts by analysts on MannKind Corporation.

What analysts predicted

48.09%UPSIDE

Target Price

$7.59

Current Price

$3.94

Analyzed by

12 Analysts

Target

$7.59

MannKind Corporation target price $7.59, a slight upside of 48.09% compared to current price of $3.94. According to 12 analysts rating.

Indian Investors' Interest in MannKind Corporation Stock

Search interest for MannKind Corporation Stock has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-42% versus previous 30 day period

MannKind Corporation Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
58
66
72
70
76
78
76
82
111
90
Gross Profit
40
47
52
52
57
60
55
61
87
68
Operating Income
7
16
16
12
26
22
5
18
-7
-2
EBITDA
9
21
13
23
18
26
9
17
-2
2
Interest Expense
5
9
12
8
7
10
6
7
13
12
Depreciation
1
1
2
2
2
2
2
2
4
6
Income Before Tax
2
10
-1
12
8
13
0
7
-20
-16
Income Tax Expense
1
0
0
1
1
0
0
0
-4
0
Net Income
1
10
-2
11
7
13
0
7
-15
-16
Net Profit Margin
2.40%
16.04%
-2.78%
16.48%
9.67%
16.79%
0.87%
9.72%
-14.25%
-18.43%

MannKind Corporation Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
174
11
27
63
65
75
99
198
285
348
Gross Profit
124
-5
7
35
40
36
42
136
208
287
Operating Income
67
-108
-76
-44
-47
-47
-64
8
72
38
EBITDA
64
-102
-75
-38
-44
-61
-56
15
77
27
Interest Expense
18
13
9
10
9
16
24
25
37
13
Depreciation
-
3
2
2
3
5
9
8
9
12
Income Before Tax
125
-117
-86
-51
-57
-80
-87
-10
30
1
Income Tax Expense
13
0
0
7
0
10
24
1
2
-4
Net Income
125
-117
-86
-51
-57
-80
-87
-11
27
5
Net Profit Margin
71.91%
-999.00%
-312.20%
-82.34%
-87.87%
-107.27%
-87.60%
-6.00%
9.66%
1.68%

MannKind Corporation Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
10
-2
11
7
13
0
7
-15
-16
Operating Cash Flow
6
3
9
22
-6
8
23
-7
-5
Investing Cash Flow
-48
-55
-41
48
5
6
-25
-291
18
Financing Cash Flow
-3
-44
-2
-86
1
-5
71
247
-35
Change in Cash
-45
-95
-34
-16
0
9
70
-52
-22

MannKind Corporation Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-117
-86
-51
-57
-80
-87
-11
27
5
Operating Cash Flow
-64
-37
-88
-28
-61
-80
34
42
18
Investing Cash Flow
16
0
-22
15
-151
4
-1
-96
-304
Financing Cash Flow
73
61
69
49
270
21
136
-137
315
Change in Cash
25
23
-41
36
57
-54
168
-191
28

Global Institutional Holdings in MannKind Corporation

Funds
Holdings
Vanguard Group Inc
5.79%
Vanguard Capital Management, LLC
4.17%
Frazier Life Sciences Management, L.P.
1.91%
Bank of America Corp
1.1%
Wellington Management Company LLP
1.06%
See all

MannKind Corporation News & Key Events

  • img

    Today's Timeline - 08 June

    Mon, 08:49 PM

    -

    MannKind's inhaled insulin, Afrezza, received FDA approval for children, showing positive data at ADA 2026.

    Mon, 09:04 PM

    -

    Jim Cramer highlights MannKind as a speculation stock on Mad Money, emphasizing its speculative nature.

Insights on MannKind Corporation

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MNKD has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, MNKD stock has moved up by 16.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 15.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 111.95M → 90.17M (in $), with an average decrease of 19.5% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 7.98M → -16.61M (in $), with an average decrease of 152.0% per quarter

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
OrganisationMannKind Corporation
Headquarters1 Casper Street, Danbury, CT, United States, 06810
IndustryBiotechnology
CEODr. Michael E. Castagna Pharm.D.
E-voting on sharesClick here to vote

Key Management of MannKind Corporation

Name

Title

Dr. Michael E. Castagna Pharm.D.

CEO & Director

Mr. Christopher B. Prentiss M.B.A.

Chief Financial Officer

Dr. David B. Thomson J.D., Ph.D.

Executive VP, General Counsel & Secretary

Dr. Stuart A. Tross Ph.D.

Chief People & Workplace Officer

Mr. Dominic Marasco R.Ph.

President of Endocrine Business Unit

Mr. Sanjay Singh M.B.A.

Executive Vice President of Technical Operations

Dr. Ajay Ahuja M.B.A., M.D.

Executive VP & Chief Medical Officer

FAQs

What is MannKind Corporation share price today?

MannKind Corporation share price today is $3.94 as on at the close of the market. MannKind Corporation share today touched a day high of $4.01 and a low of $3.83.

What is the 52 week high and 52 week low for MannKind Corporation share?

MannKind Corporation share touched a 52 week high of $6.51 on and a 52 week low of $2.23 on . MannKind Corporation stock price today i.e. is closed at $3.94,which is 39.48% down from its 52 week high and 76.68% up from its 52 week low.

What is MannKind Corporation's market capitalisation today?

MannKind Corporation market capitalisation is $0.00T as on .

How to invest in MannKind Corporation Stock (MNKD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for MannKind Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in MannKind Corporation Shares that will get you 0.3807 shares as per MannKind Corporation share price of $3.94 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy MannKind Corporation Stock (MNKD) from India?

Indian investors can start investing in MannKind Corporation (MNKD) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in MannKind Corporation stock (as per the Rupee-Dollar exchange rate as on ). Based on MannKind Corporation share’s latest price of $3.94 as on June 19, 2026 at 8:46 am IST, you will get 2.5381 shares of MannKind Corporation. Learn more about fractional shares .

What are the returns that MannKind Corporation has given to Indian investors in the last 5 years?

MannKind Corporation stock has given -7.51% share price returns and 27.24% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?